agrossfarm, always appreciative of your replies/questions - thank you.
The reason I care about Biotech Beast (today) is because just recently he published a piece that was mostly supportive of OMER. Sort of odd he abruptly ended coverage.
Since the IgAN debate has been reignited, it's prompted me to go back and review articles/data, whatever I can find. Came across a few interesting snippets, like this from NCBI: https://
www.ncbi.nlm.nih.gov/pubmed/28863793 "The role of immunosuppression in IgAN remains controversial despite a growing evidence base of randomized controlled trials (RCTs). In IgAN with nephrotic syndrome the role for corticosteroids is limited to cases with minimal change on light microscopy. In crescentic IgAN, the use of immunosuppression is supported only by anecdotal data, and outcome may be poor especially when glomerular filtration rate is impaired severely at presentation or there are pathologic features of chronic injury."
Also, I read a comment stating there wasn't much talk about IgAN at the shareholders meeting, and I'm trying to investigate in an attempt to connect the dots (maybe it's nothing, but I'm interested in learning more). Hence the reason I pose these questions/topics on this board. Learn a lot from all members on this board.
Thanks again